Stock Rating Downgrade
In the last week the Value Trend Rating for Ligand Pharmaceuticals Inc (NASDAQ: LGND) weakened from B to C reflecting eroding fundamentals and low Appreciation Potential.
Recent Price Action
On 9/10/24, Ligand Pharmaceuticals Inc (NASDAQ: LGND) stock declined slightly by -0.5%, closing at $102.23. However, this decline was accompanied by unusually low trading volume at 52% of normal. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -3.4% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, LGND is expected to continue to be an important Value Builder.
Ligand Pharmaceuticals has a current Value Trend Rating of C (High Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Ligand Pharmaceuticals has a slightly negative Appreciation Score of 32 but a very high Power Rating of 93, with the High Neutral Value Trend Rating the result.
Be the first to comment